New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2014
10:40 EDTMDR, CTRP, TRIP, HZNP, OLEDOptions with decreasing implied volatility: OLED HZNP TRIP CTRP MDR
News For OLED;HZNP;TRIP;CTRP;MDR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2015
06:10 EDTTRIPTripAdvisor Instant Book continues to gain traction, says Piper Jaffray
Piper Jaffray analyst Michael Olson says that while weakness in international cost-per-clicks drove weaker than expected Q2 results and lowered 2015 guidance, TripAdvisor's (TRIP) Instant Book continues to gain traction. The company confirmed that Hyatt (H) is now on the platform, Olson tells investors. He lowered his price target for shares to $95 from $100 and maintains an Overweight rating on the stock.
July 23, 2015
19:06 EDTTRIPOn The Fly: After Hours Movers
UP AFTER EARNINGS: Amazon (AMZN), up 17.2%... Marketo (MKTO), up 15.4%... Juniper Networks (JNPR), up 9.9%... NetGear (NTGR), up 9.2%... Qlik Technologies (QLIK), up 9.1%... LogMeIn (LOGM), up 9.9%... Pandora (P), up 10.3%... Mitek Systems (MITK), up 7.8%... Proofpoint (PFPT), up 5.1%... Supreme Industries (STS), up 4.7%... Skyworks (SWKS), up 3.6%... IGI Laboratories (IG), up 3.7%... Maxim Integrated Products (MXIM), up 4.1%... Boyd Gaming (BYD), up 4.1%... Trinity Industries (TRN), up 5%... Trinity Industries (N), up 3.2%... Starbucks (SBUX), up 4.5%. ALSO HIGHER: Qorvo (QRVO), up 2.7% after Skyworks reported quarterly results. DOWN AFTER EARNINGS: TrueCar (TRUE), down 33.1% after reporting quarterly results and cutting fiscal 2015 revenue guidance... Tripadvisor (TRIP), down 9.2%... Align Technology (ALGN), down 7.4%... Capital One (COF), down 4.9%... PMC-Sierra (PMCS), down 9.1%... athenahealth (ATHN), down 2.1%. ALSO LOWER: Sunesis Pharmaceuticals (SNSS), down 59.7% after giving vosaroxin regulatory update... Avalanche Biotechnologies (AAVL), down 5.6% after CEO Thomas Chalberg, Jr., Ph.D. resigns and Hans Hull name interim CEO.
17:27 EDTTRIPTripAdvisor sees FY15 total revenue growth in 'low-to-mid 20s'
TripAdvisor said on its Q2 earnings conference call, "As it relates to guidance, based upon our view into international CPC pricing today, we are tempering our near-term outlook. We now expect 2015 total revenue growth to be in the low to mid-20s, and EBITDA growth in the low to mid-single digits. Our guidance reflects recent business trends and foreign exchange rates as of today, and does not assume future positive or negative FX movements. As such, future changes in FX and related effects on users and partners could positively or negatively impact our outlook."
16:16 EDTTRIPTripAdvisor reports Q2 EPS 54c, consensus 55c
Subscribe for More Information
15:04 EDTTRIPNotable companies reporting after market close
Subscribe for More Information
14:38 EDTTRIPTripAdvisor July weekly 93 straddle priced for 8% movement into Q2
12:13 EDTTRIPTripAdvisor technical notes ahead of earnings
Subscribe for More Information
July 22, 2015
13:33 EDTTRIPTripAdvisor July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
July 21, 2015
11:28 EDTHZNPDepomed says revised Horizon proposal includes no change to amount of stock
Depomed (DEPO) confirmed that it has received a "purported revised, highly conditional, unsolicited and non-binding" proposal from Horizon Pharma (HZNP) to acquire all of the outstanding shares of Depomed in an all-stock transaction currently valued at $33.00 per share. Depomed said its board, in consultation with its independent financial and legal advisors, will carefully review and evaluate the revised proposal to determine the course of action that it believes is in the best interests of the company and its shareholders. Depomed added: "Today's purported increase does not reflect any increase in the amount of Horizon stock that the Depomed shareholders would receive, nor any increase in the pro-forma ownership for the Depomed shareholders, and is the result of the trading value of Horizon's stock having increased since it made its initial offer." Depomed previously rejected the prior proposal, made May 27, to acquire all outstanding common shares of Depomed in an all-stock transaction then valued at $29.25 per share.
08:34 EDTTRIPTripAdvisor shares should be bought on any weakness, says Oppenheimer
Oppenheimer is upbeat on the 2H15 outlook for online travel, due partly to what it says are higher inventories, improving site traffic, and a solid industry backdrop. The firm says that TripAdvisor's site traffic is accelerating, while its mobile conversions appear to be improving. Consequently, the firm is more confident that the company's hotel inventory is selling well. Oppenheimer introduced a $105 price target on TripAdvisor and reiterated an Outperform rating on the name.
07:02 EDTHZNPHorizon Pharma increases offer for Depomed to $33.00 per share
Horizon Pharma (HZNP) announced that it has increased the value of its all-stock acquisition proposal to $33.00 per share from $29.25 per share, contingent on Depomed entering into good faith discussions regarding a transaction. The increased offer represents a 60% premium to the closing price of Depomed on July 6, the day prior to when Horizon's initial proposal was made public.
07:01 EDTHZNPHorizon Pharma increases offer for Depomed to $33.00 per share
July 20, 2015
10:33 EDTHZNPDepomed suitor Horizon Pharma advances after raising outlook
Subscribe for More Information
09:50 EDTHZNPHorizon Pharma CEO says 'here to stick it out' regarding Depomed deal
Subscribe for More Information
09:50 EDTHZNPHorizon Pharma CEO says Depomed proposal 'shareholder friendly'
Subscribe for More Information
09:22 EDTHZNPOn The Fly: Pre-market Movers
Subscribe for More Information
07:16 EDTHZNPHorizon Pharma up 5.2% after reporting preliminary Q2 revenue, raises FY15 view
Subscribe for More Information
07:05 EDTHZNPHorizon Pharma raises FY15 revenue guidance to $660M-$680M from $590M-$610M
Consensus $611.6M. Raises FY15 adjusted EBITDA guidance to $265M-$280M from $235M-$250M.
07:04 EDTHZNPHorizon Pharma sees Q2 revenue $170M-$172M, consensus $138.26M
05:48 EDTTRIPTripAdvisor price target raised to $100 from $92 at Ascendiant
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use